COMPUGEN LTD (CGEN)
IL0010852080 - Common Stock
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Participate in Two Upcoming Investor Conferences
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023
CGEN stock results show that Compugen missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Compugen (NASDAQ:CGEN) just reported results for the fourth quarter of 2023.Com...
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
7 Speculative Stocks to Double Your Money THIS Year
Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around.
Compugen regains compliance with Nasdaq's minimum bid price requirement (NASDAQ:CGEN)
Compugen regains compliance with Nasdaq's minimum bid price requirement after receiving a non-compliance notice for failing to maintain $1.00 share price.
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery,...
Compugen stock rockets 160% on Gilead development deal (NASDAQ:CGEN)
Compugen (CGEN) shares rocketed 160% in morning trading Tuesday after the Israeli drug developer announced a development deal with Gilead Sciences (GILD) worth
Why Are Stocks Up Today?
Stocks are up today and investors wondering why will want to keep reading as we have a breakdown of the market's rally on Tuesday!
Why Is Compugen (CGEN) Stock Up 189% Today?
Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning!
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
7 Promising Penny Stocks With the Potential to Defy Expectations
While market speculation can get extremely dangerous, those who understand the risks may like these high-potential penny stocks.
Compugen receives non-compliance notice from Nasdaq (NASDAQ:CGEN)
Compugen receives a notice from Nasdaq for non-compliance with minimum bid price requirement; has until May 1, 2024 to regain compliance.
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery,...
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present at Single Cell Genomics 2023 Meeting
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Reports Second Quarter 2023 Results
Advancing enrollment in two proof-of-concept studies evaluating triple blockade of DNAM-1 axis in patients with microsatellite stable colorectal cancer and...
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...